UCI 趙 Chao Family Comprehensive Cancer Center



Breast Disease-Oriented Team

Clinical Research Treatment Trial Flowchart
CRC Contact: GRP - CTU Breast Coordinators (CTUBreastCRC@hs.uci.edu)
Clinical Research Manager: Juan Miranda

Cognitive Impairment

Open to Accrual | Low Accruing | Pending Activation/Suspended

ALL

UCI 24-05
Riluzole PO vs. Placebo PO
Perceived worsening of *cognitive function*
BREAST COHORT FULL
PI: Chan
CRC: Randy Kang
Accrual: 26/39

UCI 25-48
Riluzole PO vs. Placebo PO
Perceived worsening of cognitive function
PI: Chan
CRC: Madeleine Phan
Accrual: 4/20

Neoadjuvant Therapy – HER2-/HER2+

Open to Accrual | Low Accruing | Pending Activation/Suspended

HER2+	HER2-
	SWOG S2206 (HER2-/low/equivocal) Arm 1: SOC AC-T Arm 2: SOC AC-T + Durvalumab (IgG1k mAb) MammaPrint Index Score MP2 required PI: Parajuli CRC: Madeleine Phan Accrual: 4/10

UCI 25-123
A Phase I Study of the Application of Lattice Adaptive Radiotherapy Protocol (LARP) for Symptomatic, Bulky Tumors

PI: Harris
CRC: TBD
Accrual: 0/5

UCI 25-48 Riluzole PO vs. Placebo PO Perceived worsening of cognitive function	PI: Chan CRC: Madeleine Phan Accrual: 0/20

Neoadjuvant Therapy – HER2-/HER2+

Open to Accrual | Low Accruing | Pending Activation/Suspended

TNBC

SWOG S2212 (SCARLET)

PI: Nafissi
CRC: Jerar Palian
Accrual: 0/7

Adjuvant Therapy – HER2-

Open to Accrual | Low Accruing | Pending Activation/Suspended

HR+

ER+

UCI 25-213 (PIKALO-2)
LY4064809 + CDK4/6 Inhibitor + ET
For aBC PIK3CA

PI: Parajuli
CRC: TBD
Accrual: 0/5

ECOG-EA1242 (RxFINE-Low)

Arm A: SOC Chemo + SOC ET + Ribo
Arm B: SOC ET + Ribo

PI: Parajuli
CRC: Madeleine
Accrual: 0/5

Adjuvant Therapy – HER2+ & TNBC

Open to Accrual | Low Accruing | Pending Activation/Suspended

HER2+

A012303 (Any HR)
Arm 1: Trastuzumab +/- Pertuzumab every 3wks for 12months
Arm 2: Trastuzumab +/- Pertuzumab every 3wks for 6 months

PI: Lavasani
CRC: Randy Kang
Accrual: 0/5

TNBC

Metastatic: HR+/HER2-

Open to Accrual | Low Accruing | Pending Activation/Suspended

1L+

UCI 19-145 (HR+/HER2-)
CDK 4/6 inhibitor+ER Regulator+Aromatase Inhibitor

CRCs: Stephany Ruiz. Michael Rodriguez, Madeleine Phan
Accrual: 21/40

UCI 25-213 (PIKALO-2)
LY4064809 + CDK4/6 Inhibitor + ET
For aBC PIK3CA

PI: Parajuli
CRC: TBD
Accrual: 0/5

2L+

UCI 22-09 (TNBC, HR+/HER2-)
XMT-1660 (ADC) – BC, EC, OC, ACC-I
Dose Esc, Backfill Cohort, Exp
SLOT RSVP REQ (HR+ COHORT TEMP CLOSED)

PI: Parajuli
CRC: Stephany Ruiz
Accrual: 7/10

Metastatic: HER2 Low, HER2+

Open to Accrual | Low Accruing | Pending Activation/Suspended

1L

SWOG-S2511 (HER2+)
De novo stage IV oligometastatic (≤ 5 lesions)
Physician's choice NCCN/ASCO guideline concordant systemic therapy for 12-24 weeks

PI: Lavasani
CRC: TBD
Accrual: 0/5

2L+

UCI 24-49 (HER2+ IHC 2-3+, HER2 Amp ISH)

Dose Esc (Ph Ib):
Cohort A: Zongertinib (BI 1810631; HER2 inhibitor) + T-DM1
Cohort B: BI 1810631 + T-DXd
Cohort K: Zongertinib+Trastuzumab

SLOT RSVP REQ (Dose Esc)

PI: Dayyani
CRC: Randy Kang
Accrual: 3/10

UCI 25-81/UCI 25-81-03 (HER2+)
Locally adv or Mets HER2+ prior T-DXd relapsed in 6month
Physician Choice then either Cohort 1 or 2
Cohort 1: Evorpacept (ALX148)+Trastuzumab+Chemo
Cohort 2: Trastuzumab+Chemo

PI: Parajuli
CRC: TBD
Accrual: 0/5

METASTATIC: 1L

UCI 26-205 (MK-2010)
A1: MK-2010 + Sac-TMT *vs*
A2: TROP2 ADC of choice-SG + Dat-DXd
OR
B1: MK-2010+Sac-TMT *vs*
B2: Pembro + SG
PI: Parajuli
CRC: TBD
Accrual: 0/5

Open to Accrual | Low Accruing | Pending Activation/Suspended

Metastatic: TNBC

METASTATIC: 1L+

UCI 22-09 (TNBC, HR+/HER2-)
XMT-1660 (ADC) – BC, EC, OC, ACC-I
Dose Esc, Backfill Cohort, Exp
SLOT RSVP REQ (HR+/ COHORT TEMP CLOSED)

PI: Parajuli
CRC: Stephany Ruiz
Accrual: 6/10

ETCTN 10546
ASTX727 (Cytidine deaminase (CDA) inhibitor + nucleoside hypomethylating agent (HMA)) + Paclitaxel + Pembrolizumab
DL-2 now open for TNBC
SLOT RSVP REQ

PI: Parajuli
CRC: Michael Rodriguez
Accrual: 1/5

UCI 24-08
SPEDOX-6 IV
SLOT RSVP REQ

PI: Chow
CRC: Erin Torrison; Breast CRC TBD
Accrual: 6/67

UCI 24-195
PF-08046054 (an ADC) monotherapy
Dose ESC (Part A) or Schedule Optimization (Part B):
PD-L1 expression ≥1 TPS, CPS, or % IC
Signal-seeking cohort: ADC monotherapy
Biology cohort: ADC monotherapy

PI: Nagasaka
CRC: TBD
Accrual: 0/6

Metastatic: Basket Trials

Open to Accrual | Low Accruing | Pending Activation/Suspended

ALL

UCI 25-106
BMS-986517 Monotherapy
HR+/Her2- and TNBC

PI: Dr. Nabar
Coord: N. Arechiga/TBD
Accrual: 0/5

UCI 24-197
TNG456 Monotherapy or Combined w/Abemaciclib in solid tumors with MTAP Loss
SLOT RSVP REQ

CRC: TBD

PI: Park
Accrual: 0/5

UCI 24-142
Phase 1 Dose Esc
Group A: VET3-TGI monotherapy by ITu injection
Group C: VET3-TGI monotherapy by IV infusion
Group B: VET3-TGI by ITu injection, Group D: VET3-TGI IV infusion combo with pembrolizumab
SLOT RSVP REQ

PI: Uchio
CRC: TBD
Accrual: 2/4

Metastatic: Basket Trials

Open to Accrual | Low Accruing | Pending Activation/Suspended

ALL

UCI 22-26

CB-03-10 (PO; AR and GR antagonist)
Part 1 (esc): adv/met solid tumor
Part 2 (exp): adv/met solid tumor or relapsed/refractory TNBC
SLOT RSVP REQ

HPB/Panc CRC: Miranda Duron
Breast CRC: TBD

PI: Dayyani
Accrual: 11/12

UCI 25-75

CRN09682 IV (an MMAE) for SST2-expressing solid tumors

CRC: TBD

PI: Dayyani
Accrual: 0/15

Open to Accrual | Low Accruing | Pending Activation/Suspended

Other Interventional/LTFU

UCI 25-43
Type 1 Hybrid Effectiveness of a Patient-Reported Outcomes

PI: Chan
CRC: TBD
Accrual: 0/5

UCI 24-87
Effect of a Methionine-Reduced Diet in Patients with Solid Tumors

PI: Arter
CRC: Keagan
Accrual: 2/25

A232403
Longitudinal Screening for Financial Hardship to Improve Outcomes in Patients with Advanced Cancer

PI: Lavasani
CRC: TBD
Accrual: 0/5

NRG CC015
E-Mindfullness for living after Breast cancer

PI: Kim
CRC: Jerar
Accrual: 0/10

Non-Treatment

Open to Accrual | Low Accruing | Pending Activation/Suspended

Non-Treatment

BASIC SCIENCE

UCI 18-136
6 slots for Cohort 1/neo-adjuvant and 13 slots for Cohort 2/adjuvant
PI: Parajuli
CRC: Caylee Carlton
Accrual: 79/100

UCI 17-05 (BRCA1 -/-, +/+)
PI: Parajuli
CRC: Billy Joel Sanchez
Accrual: 49/75

Alliance A232403
DOT Approved
Financial Hardship study
PI: Lavasani
CRC: TBD
Accrual: 0/5

SUPPORTIVE CARE

UCI 24-64
High fiber diet as therapy response and reduce recurrence
PI: Whiteson
CRC: TBD
Accrual: 0/60

UCI 25-115
Couples Intervention for Young Adult Cancer Survivors: A Pilot Study
PI: Hoyt
CRC: TBD
Accrual: 0/5

Non-Treatment

HEALTH SERVICES RESEARCH

UCI 25-25

PI: Eakin
CRC: TBD
Accrual: 0/150